GlassScriptPhysician profile
Gregory A St John
NPI 1124023056
$4,892.75
in general payments reported to CMS, 2019-2025
30 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $566 · 2021: $952 · 2022: $392 · 2023: $336 · 2024: $228 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,179.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $559.93 | 2019-2023 | |
| Amgen INC. | $504.40 | 2019-2021 | |
| Abbott Laboratories | $479.93 | 2020-2023 | Mitraclip, Perclose Prostyle, Aveir |
| Janssen Pharmaceuticals, INC | $474.16 | 2019-2024 | Xarelto |
| Medtronic, INC. | $400.02 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Abiomed | $174.56 | 2019-2025 | Impella |
| Celonova Biosciences, INC. | $155.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $139.66 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.18 | 2021-2024 | Lifevest |
| Baxter Healthcare | $76.62 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $67.92 | 2019 | |
| Boston Scientific Corporation | $57.11 | 2019-2020 | |
| Gilead Sciences, INC. | $54.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.25 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $48.98 | 2023-2025 | Irrisept |
| Actelion Pharmaceuticals US, INC. | $40.56 | 2019 | |
| Shockwave Medical, INC | $36.24 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.51 | 2023-2024 | Jardiance |
| Elutia, INC. | $30.47 | 2021 | |
| Philips North America LLC | $30.33 | 2020 | |
| Sanofi-Aventis U.S. LLC | $28.70 | 2020 | |
| Terumo Medical Corporation | $27.46 | 2025 | Angio-Seal |
| Novo Nordisk INC | $25.75 | 2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $24.65 | 2019 | |
| Genzyme Corporation | $21.15 | 2022 | |
| Irhythm Technologies, INC. | $19.07 | 2020 | |
| Livanova USA, INC. | $18.00 | 2021 | |
| Biosense Webster, INC. | $15.73 | 2024 | Carto 3 |
| Bardy Diagnostics, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory St John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.